FIELD : medicine.SUBSTANCE : invention refers to medicine and can be used for prediction of severe clinical course of diabetic polyneuropathy (DPN) and development of diabetic foot syndrome. That is ensured by analysing the patient' s diabetes with a serum level of the tropomyosin kinase receptor (TrkB) by enzyme-linked immunosorbent assay, additionally the glycated blood hemoglobin level is determined. Thereafter, a coefficient is calculated by a regression model K = 0.3?*?HbA1C?+?0.4?*?TrkB, where K is a coefficient, 0.3 is a regression constant, HbAlC is a glycated hemoglobin level, 0.4 is a regression constant, TrkB is a serum level of tropomyosin receptor of kinase type B. Coefficient K> 5 indicates high probability of severe clinical course of diabetic polyneuropathy and high risk of developing diabetic foot syndrome.EFFECT : using this method enables predicting severity of diabetic polyneuropathy by determining degree of carbohydrate metabolism compensation, which eliminates the possibility of detecting another neurological pathology accompanied by a demyelinating process, as well as enables to take early therapeutic measures to prevent these complications.1 cl, 3 ex